Emodin Decreases Tumor-Associated Macrophages Accumulation and Suppresses Bladder Cancer Development by Inhibiting CXCL1 Secretion from Cancer-Associated Fibroblasts
Authors:
- 20 March 2025
- journal article
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 77 (6) , 706-721
Abstract
Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in the bladder cancer (BC) microenvironment (TME). However, the detailed mechanisms underlying TAM-CAF communication and their contributions to BC progression remain incompletely understood. Emerging evidence shows that Emodin exerts anti-tumor effect on several tumor models by targeting TME. To date, the impact of Emodin on BC has not been previously reported. Our study firstly demonstrated that Emodin significantly inhibited tumor growth and reduced TAM accumulation in a murine BC model. Emodin markedly decreased serum levels of multiple chemokines in tumor-bearing mice, with CXCL1 showing the most pronounced reduction. Strikingly, Emodin selectively suppressed CXCL1 secretion in CAFs but not in TAMs or tumor cells. Furthermore, the decrease in TAM migration induced by Emodin was dependent on CAF-derived CXCL1. Using a subcutaneous tumor model, we found that Emodin failed to inhibit tumor growth when CXCL1-deficient CAFs were co-injected with tumor cells, underscoring the critical role of CXCL1 in this process. Bioinformatics analysis further revealed that elevated CXCL1 levels correlated negatively with invasive/metastatic potential and overall survival in BC patients. In conclusion, our findings establish that Emodin delays BC progression by disrupting CXCL1-mediated crosstalk between CAFs and TAMs.Keywords
Funding Information
- Key Research and Development Plan of Shaanxi Province (2018SF-342)
- Logistics Research Project of China (AWS17J014, BWS18J011)
- Medical Science and Technology Youth Training Project of Ministry of Health (14QNP093)
This publication has 73 references indexed in Scilit:
- Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1RBiomaterials, 2024
- The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapyBiomedicine & Pharmacotherapy, 2023
- Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinibCancer Communications, 2023
- Tumor-associated macrophages induce inflammation and drug resistance in a mechanically tunable engineered model of osteosarcomaBiomaterials, 2023
- Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targetingAdvanced Drug Delivery Reviews, 2022
- Emodin attenuates severe acute pancreatitis-associated acute lung injury by suppressing pancreatic exosome-mediated alveolar macrophage activationActa Pharmaceutica Sinica B, 2021
- CAFs and TAMs: maestros of the tumour microenvironmentThe Journal of Pathology, 2016
- Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathwayEuropean Journal of Pharmacology, 2016
- Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungsBreast Cancer Research and Treatment, 2014
- Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growthMolecular Carcinogenesis, 2013